# Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

> **NCT07492628** · PHASE1 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 42 (estimated)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Upper Tract Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** EB-DT-NK-UC101
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07492628
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-06-14
- **Final completion:** 2028-05-17
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492628, "Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07492628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*